Treatment Options of First-Line Tyrosine Kinase Inhibitors and Subsequent Systemic Chemotherapy Agents for Advanced EGFR Mutant Lung Adenocarcinoma Patients: Implications From Taiwan Cancer Registry Cohort

SHENG-KAI LIANGLI-TA KENGCHIA-HAO CHANGWen, Yueh-FengYueh-FengWenMENG-RUI LEECHING-YAO YANGJANN-YUAN WANGJEN-CHUNG KOJIN-YUAN SHIHCHONG-JEN YU2021-03-112021-03-1120212234-943Xhttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85099742333&doi=10.3389%2ffonc.2020.590356&partnerID=40&md5=b81f9bc6241932c9450909e70654077chttps://scholars.lib.ntu.edu.tw/handle/123456789/551903[SDGs]SDG3Treatment Options of First-Line Tyrosine Kinase Inhibitors and Subsequent Systemic Chemotherapy Agents for Advanced EGFR Mutant Lung Adenocarcinoma Patients: Implications From Taiwan Cancer Registry Cohortjournal article10.3389/fonc.2020.5903562-s2.0-85099742333